Dr. Marla Dubinsky
CEO at TRELLUS HEALTH PLC
Replay available
Interim results for the six months ended 30 June 2022 hosted by Trellus Health (LSE:TRLS) on Investor Meet Company, held 2022-10-03.

On 6ix: 6ix.com/event/trellus-health-plc-trls-interim-results-for-the-six-months-ended-30-june-2022
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Good afternoon, ladies and gentlemen, and welcome to the TRLS Health PLC Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Just simply type in your questions at any time and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, we'd like to submit the following poll. And if you'll give that your kind attention, I'm sure that will be well received by the company. And I'd now like
0:33 to hand over to Steven Young, CFO Julian Baines, Chairman and Doctor. Marla Dubinsky, CEO. Good afternoon. Good afternoon. Thank you, Mark. Good afternoon, everybody. Again, I'm pleased to be presenting on our interim results for TRLS HEALTH. As as noted, I'm doctor Marla Dubinsky from Mount Sinai School of Medicine, New York, and I have taken over and assumed the role of CEO as of July 19. And I'm here with our CFO, Steve Young, as well as introduce our COO who's not here today, but has really been instrumental in helping to move the company forward as I will present today, recognizing that almost everything that I'm gonna be presenting today has really occurred, to drive the business forward really in the last ten weeks.
1:24 So I thought I would start with an, of course, the disclaimers, but let's move to the overview of the company. For those of you who may or may not remember what we are or know what we are, we're really the first, digitally delivered health company, that is focused on building self management solutions and tools for patients with chronic conditions to be able to take charge of their health and change their health behaviors for better outcomes. We have used a we use a proprietary methodology that was developed and validated at Mount Sinai by myself and my cofounder, doctor Lori Kiefer, which is the first resilience based self management solution out there in the market for chronic conditions. There are three main components to TRLS. We've got a platform that actually delivers our resilience method and self management tools along with a team that enforces and facilitates the behavior change strategies that we deliver through our platform.
2:24 We have a very clear, business strategy and model. We sort of have dual business model. We have both a b to b to then deliver to the customer as well as a direct to consumer model, which really is there to help bring patients on the platform, learn, refine our, our strategies, and make sure that we're driving the right business forward with our larger commercial market of b to b. We have many contracts that are either shortly and or signed, and I'll walk you through that, as well as advancing our other b to b, pipeline. The other thing is we are starting an inflammatory bowel disease and have started and raised back in May 2021 based on our initial focus given where the self management solution was developed and validated. However, excited to note that our expansion to irritable bowel syndrome, which is another type of chronic GI condition, is set to be launched in January 2023.
3:26 And, of course, we'll, highlight as we move through the presentation about our cash runway, which has been extended to 2025, and talk a little bit more about how we've done that and how disciplined we've been with our cash. Because it's a novel method and this has never been brought out to the management of chronic conditions, I thought I would just take a minute to remind you the difference between the TRLS approach and what is traditionally a traditional psychology, approach, which most apps out there are saturated on the market with many apps that have the same, goals, which is to treat the end game of mental health, which is people who've already developed anxiety or depression or managing stress only, very single point solutions. That doesn't really change the cost or health status of many patients versus taking a very proactive approach, which is what TRLS does.
4:19 Our method uses positive psychology principles, which is a completely different approach where we focus on changing behavior and health behaviors to actually improve the health status and actually prevent mental health decline. So it's a very proactive approach to changing the way someone acts and or thinks in the face of having a chronic illness and all the challenges that are in front of them as it relates to complicated medication regimens, also lifestyle choices, how to effectively communicate with a social network and your provider. So it's a really unique approach that typically resilience training has been mostly in folks with PTSD or, in the mental health space and the fact that we've been able create a tool that actually measures someone's resilience and be able to go in and teach people on how to be more resilient. Resilience is one of the few psychological traits you can actually learn. So the ability to transform the lives of people with chronic conditions is the lens for which TRELLUS delivers, its method.
5:25 I noted that we started with inflammatory bowel disease, and just in case you're not familiar with it, the word IBD means two things, Crohn's disease and ulcerative colitis, which is the diseases that I've been treating for twenty five years plus. And just noting that these are very, very chronic illnesses diagnosed in the young, which means a lifetime of cost that is very impactful to any health care system as well as treated with very expensive medications, surgeries. There's a huge sort of brain brain, gut, or mind body experience that these patients face, making it difficult to sort of control the symptoms and control the cost, very high mental health burden. And similarly, irritable bowel syndrome, which is actually not a genetic inflammatory immune disease. It's actually a what we call disorders of brain gut, meaning there's a huge functional component between the brain and the gut. And, basically, instead of having migraines when you're stressed, patients have these GI symptoms, and it's really debilitating and actually impacts your ability to actually work and get through the day to day. So both of them are in need for a sort of a resilient self management solution so that patients are not relying on the low value health care system and basically putting them in charge of their health so they can control and function in a day to day setting.
6:47 So when we talk about our dual business model, it's really important to understand that in order to actually make sure you have the right product to deliver to your paying clients, you need to make sure that you're delivering what the end user really needs and wants. And we've been fortunate enough to actually have end users on the platform sort of using almost like a phase two type of study before we get into phase three where you take your learnings from a smaller patient population, refine and observe, create data that actually helps our conversations with our end game strategy, which is really our business to business, which is delivering it to the same consumer that we do directly to the consumer. And what this slide shows you is that there's different value props for who the end user
7:34 is if it's directly to the end user or whether or not we're going through our business partners. Because business partners, which are really health plans, employers, companies that actually take on the risk of the health plans and say, we're gonna partner with people out there, and we're gonna deliver you, your patients at lower cost, and really, hiring us to sort of be that resilience or self management part of their value prop. At the end of the day, anybody paying for health care really wants to reduce the cost and knowing that the biggest cost driver in patients with these chronic conditions, GI and non GI conditions, is driven predominantly by the inability for the patients to actually self manage and spending a lot of time and money in the health care system due to the mental health burden that overlays folks who are diagnosed at the age of 18, 19 told, oh, sorry. You have an incurable chronic condition. You're gonna have to take infusions or injections or pills every day, and you may end up in the Operating Room if you don't do it. And how does it actually take someone function in the daily activities really requires a self management program. And you could see here sort of how our revenue sources are based on who our customer is and who's paying.
8:48 So I'll hand it over to to Steve before we get into all the various b to b channels and all of our customer channels opening the doors to get patients more patients on the platform. Thank you, Mara. Just like with with some of the financial highlights, obviously, the main point at the top is the net cash has reduced from 32,000,000 at the year end to $24,000,000 on the June 30. But more importantly, some of the key things which have been put in place since the change in management on the July 21 of this year is the significant cost reductions that have been implemented. Mainly on salaries, outsourced software development where we renegotiated contracts, and the spend on external consultants who are providing a lot of advice, probably with the best retentions, but probably wouldn't.
9:33 I think we weren't getting true value for money for necessarily all of them.
9:37 And the combined effect of all those savings is reduced our monthly burn rate by 36% from roughly about $1,100,000 to around $700,000 per month. And that's ensured now that we have significant cash resources until early twenty twenty five, assuming the current levels of revenue, which are worst case because that's assuming very, very little revenue also. That's it. So ever. But whilst maintaining the capital investment. This next slide is just a little sort of ready reckoner as I call it. Effectively, trying to give you a rough idea of the type of sort of cut the numbers of customers we required out of the marketplace of both the IBD and the IBD marketplace, the entire 33,000,000 sort of market market, what percentage of that market we would require to breakeven given a mix of whether it's business to business or direct to customer including I e d and I b s.
10:37 That's what sort of mix we need based on average monthly enrollment fees, what we need. So if you do a survey, in this particular instance, you can see the range. We'd need between 7,000 people and 14,000 people on the platform at any one one point in time to reach our breakeven point. Yeah. I think it's just a matter of of really yeah. When, but also understanding that b to b still remains our North Star. And the goal is, as I noted, to use the direct to consumer model to really drive the b two b commercial market. And we recognize that that's our goal, and that's the strategy. And you'll see in just a moment that that is front and center of the way we're going to, deliver. So as I walk you through the different, b to b types of customers, but also understanding, the reach and the channels that we we use to get there. So starting with the left, so we've been in late stage discussions and already due diligence discussions with two of the largest health plans in The US.
11:38 Also, a Medicaid plan out of New York, where we're in the final contracting phase. The third, employer plan, which the third model is our employer plan, and this actually, I can officially say, is a signed contract, and this is with Mount Sinai. As an employer, I think the most important thing to understand about an employer is that they are paying for all of their employees with IBD first and then rolling out to the other chronic conditions that employees have, close to 50,000 employees, that that TRLS will be available and paid for as a wellness service for employees. Employees employers want positive, productive employees, but also saving cost on health care, and they understand that TRLS is a way for them to deliver the wellness product to their patients and also, to be able to, deliver cost savings on the spend that they spend on the health care for their employees.
12:38 And the fourth is a New York state provider offering this as a wellness benefit to certain, members or patients that are part of one of the large labor unions in New York state. So the ability to say, alright. We as providers offer services to multitude of insurance, members, and one of them that comes to Sinai and trust Sinai with their patients is a big labor union and be able to actually, improve the lives and wellness of those patients in that labor union as well. So just really emphasizing that there are multiple channels for which TRLS could be able to offer, health and wellness and cost savings and improved outcomes to those in various health plans across sort of the spectrum of health plans. The other important sort of business opportunity which has come up and mainly driven by the fact, of course, I understand that the pharmaceutical business is really stuck to how can we ensure that patients are actually taking their meds, continue to refill, have some customer long term customer engagement over time. And one of the things that although they have a lot of money being spent on these sort of what we call patient support hubs where they have co pay assistance, they have financial assistance, what they don't have is an opportunity to actually change health behaviors and have patients be able to be adherent to the medications so they continuously refill their medications. That is the biggest sort of financial downstream loss to pharmaceutical companies is patients just not staying on their drug.
14:10 Either moving to another drug or just deciding that they don't need this drug anymore, that's really lost revenue. So the ability to partner with a program like TRLSS laser focused on adherence and medication adherence training using our self management modules and and training really helps them obviously with downstream ROI to be able to actually partner with TRLS to keep patients on their on their medication. And the other really important pharmaceutical approach is really the fact that there's about 230 plus assets that are planned to be in clinical trials for IBD patients. There's just not enough patients that are identified by the traditional way that pharma are using to identify potential, patients who would be randomized into a clinical trial starting at phase two and then into phase three trials.
15:02 So really recognizing that TRELLUS will have very robust, precise data on those patients with these conditions to be able to actually prescreen patients so that there's less screen failures that are being sent to the sites to be enrolled. So, essentially, we're being able to be more precise in saying you're gonna have less money thrown out the door by paying a clinical trial site to just fail screen patients. When you actually go to enroll them, they're gonna meet the inclusion criteria with much more precision and be able to spend less money on failed screening. This is a major, major, line item for pharma in order to get their drugs to market faster and to spend less money wasted on those patients who don't actually randomize into the trial.
15:48 So that's a really big value add for pharma. So this is sort of a new line item, a different business model for TRLS, which allows us it's not as much dependent on how many patients on the platform if you understand. It's based on our delivery of being able to actually secure patients to stay on meds and also be able to screen patients, prescreen for clinical trials. And sort of one of the other important things, I think, for everyone to understand is the fact that although we using our DTC, again, not to be our main business model, but to drive our b to b customer, one thing that we do have that really is beneficial to TRELLUS is that we have an end user population where there's an urgency to sort of solve these problems. They will not and have not been able to get any form of self management digital solution at all, let alone using a resilience based method that worked that works every day at Mount Sinai and that worked to significantly reduce cost, is the fact that in h two of twenty twenty two, since we left in May, we said we're gonna go out. We're gonna get patients on in the consumer space, get more end users to help us drive the data, make sure that we test and retest the platform to make sure we're delivering. And one of the questions that we got when we delivered in May about this, this approach is how are patients gonna pay for it? We're in a recession. It's a difficult time. How are you gonna make this happen? Well, I'm happy to say that we were able to partner with some key patient advocacy groups who actually sponsored
17:20 these patients on the platform. Therefore, there's no out of pocket from patients, and we've been able to get it paid for and get the data we need to drive our b to b, business. Now for 2023, we're gonna continue to build on, bringing the solution to consumers who need us, but we have pretty well the two only channels that no other company has, which is to bring this type of solution to patients and providers. I'll start with the middle one. The Crohn's and Colitis Foundation of America is the national patient advocacy organization for patients. They are the ones that are the most trusted source of bringing solutions to members. So all three mem three million IBD patients rely on the Crohn's and Colitis Foundation to be sort of the growth channel for them to get accurate, precise, effective approaches to the disease. So we've just signed a licensing agreement for for the CCFA who will we will be their key, turnkey, exclusive approach to resilience based self management for the IBD patient population, which is a tremendous, add value add to their members as well as obviously for TRLS. And probably the thing that's sort of hottest off the press is we just signed a partnership agreement, with the, American College of Gastroenterology, which is our largest GI society in The US for which there are 16,000 of us. That's all of us. That's 16,000
18:51 gastroenterologists nationwide who who manage all chronic GI health conditions across The US. We are now their exclusive self management solution for GI conditions. So we are very excited to be able to launch this partnership at our national meeting, October 22 in Charlotte, North Carolina.
19:14 And you will hear a lot more about it because there's gonna be a lot more, press, etcetera, around the importance of bringing TRLS to the multitude of, IBD and IBS patients, in the country. So this was really sort of you cannot get more direct to either the people that are managing these patients or the patients themselves. There's nowhere else to go. This is it. So the fact that both the biggest patient advocacy group as well as the largest provider advocacy organization views TRLS as the exclusive delivery of the self management solution should give you a lot of confidence in the credibility of one that I bring to the table because now I'm able to sit in front of them and let them know exactly what we're gonna do because this is what I do every day for my patients, and I can assure them that we're gonna be able to deliver this to either the providers who are gonna have a lot of faith in what myself and my cofounder bring and what TRLSS represents to them in the scientific and academic community.
20:14 So as we approach sort of where we're spending our q four time getting ready for all of the you know, this bringing all these, end users to the table and delivering our solution to them is obviously our product is an evolution to make it, usable and featuring it towards having a second disease now on board, which will be irritable bowel syndrome, as I noted, which will be we originally had talked about bringing it on sometime in late h one. Well, actually, we've been able to move quicker in the product and work with our technology and our developers to actually bring IBS to be wrapped in a bow, as well as IBD. So in January, we're gonna be able to really roll out to our employers, our cons our end users, and carry out and deliver on what we said we were gonna do from day one. And we also are launching our learning management system, which we've automated all of the behavior change, modules now. So it's gonna be all stand alone. So we have just a resilience and self management curriculum that's all automated, and the coaching team are there to help facilitate and make sure patients actually progress through their curriculum.
21:23 And I'm excited now that we're launching with GI On Demand and the American College of Gastroenterology. GI On Demand is the platform that actually delivers the ACG members and providers out there, these tools that we're gonna be able to actually we've developing a provider app where it's just a pure communication, almost like a WhatsApp regarding TRELLUS between providers and the TRELLUS team. So we continue to ensure we're driving, all of that to, be the communication so that the providers are aware of what their patients' needs are so we can get them and better effective communication with their providers so they don't end up using the hospital and the emergency room visit to try and get the attention of the provider. Technology wise, obviously, security compliance and de identification of data, to be able to actually deliver reports and be able to carry through on our security and compliance road map. And, of course, we need to continue to message and make
22:18 sure that we're offering the right branding and messaging so that even when we open the doors, the doors have been opened, that TRELLUS actually delivers on what we're actually doing, which is actually building and having patients master the art of self managing so that they themselves are improving their health behaviors and understanding prevention of illness and being able to drive better health status in general. And finally, this is just sort of looking at our outlook. I sort of summarized, and I'll leave it up here as we, head into some of the question and answer. I see some of you sending your questions, so thank you so much. But just, you know, focusing, and we'll come back to sort of these sorta emphasizing and putting sorta exclamation marks, across these three lines of where we're gonna go in the future and where we are today. So
23:05 I'm gonna just start. Mark, is it okay if I head into the Yeah. Today? Let me just give you a short pause and have a time to scroll through because you can see you've had quite a few questions through today's meeting. And firstly, thank you to everybody for your questions. But please do continue to submit those questions Just using the Q and A tab on the right hand side of your screen, which is Marla and Steve can take a few moments to review those questions. I'd like to remind you that a recording of this presentation along with a copy of the slides and the published Q and A can be accessed via your Investor Meet company dashboard. I've given you no time at all, Marla, but there we are. You've had
23:37 a number of questions. If I could just hand back to you, if I may ask you just to read out those questions and give a response where it's appropriate to do so, I'll pick up from you at the end. Yeah. So So I'm gonna, approach the first one which said about outside The US. So the good news is is that with us sort of making the chain pivotal changes to automate our digital strategies and have a coaching model. Therefore, we're not using any kind of licensed, nurses, or we don't need to worry about licensing requirements and trying to get everybody licensed across every commercial health plan. With our coaching model, we're actually able to be in Canada, and we already started expanding in Canada. So we actually have been able to go across the 50 states since I last saw some of you in May and also across, Canada.
24:27 And we'll be looking to move beyond Canada as well as we evaluate some of the regulatory and compliance and security in terms of conditions requirements. So that's that's the first place I wanted to to mention. There was also a question about exclusivity, and that really lasts itself with, our partners because, for example, the American College of Gastroenterology, you know, they've vetted a lot of companies, and they know that we're sort of, for them, we represent the turnkey solutions. And as long as we're able to, as long as we're able to actually deliver on what we say we're going to to providers and patients, we are gonna continue to be their exclusive IBD solution.
25:13 And we even have discussed that if they come to us and say, hey. We're evaluating another solution. We'll say, well, wait a minute. We can probably provide that for you. And we have that in the agreement that if we can come through and we can provide them something that one of our competitors or partners out there have access to that we don't quite yet, we get sort of right of first
25:33 refusal. So, the question was, by the way, that I'm answering because I'm, like, used to doing Zoom q and a on my talks, is, it said, you mentioned exclusivity. How long does that last, and what are they committed to do? So that was that, question, and the other one was about rolling out beyond the The US. So I think that one of the other questions that I'd like to read out, was, how do you balance patient data privacy and the opportunity to monetize the platform? And I think, you know, we've thought a lot about that, and, you know, we're very clear that this is de identified aggregate data. A lot of our pharma partners, when we look at what we promise as reporting, because that really ties back, you know, a lot of it is how many people logged on, how many people completed the platform, what's the demographic in aggregate data. Like, are they more females?
26:26 Are they more people who live on the West Coast versus the East Coast? What's the, average age of folks that actually are able to complete the program? So it's more aggregate data. You know, we're not selling, identifiable data. That is not what we're doing because, also, a lot of our customers, they have their own regulatory about what they're what they're allowed to do. So so far, our discussions have been clear that our regulatory guidance and the way we've designed what we deliver to them reporting has been accepted by by the by our partners. Uh-huh. The there was a good question about IBS as a very large opportunity, but very competitive. How do you manage this entry into the market? So let me talk to you a little bit about what is out there for IBS and what what TRLS is versus every other cognitive behavioral therapy app ever developed.
27:20 CBT, giving something prescribed for twelve weeks, not including the providers as part of the solution, not providing anything but one technique to actually manage IBS, not taking to account the whole mind body sort of approach to IBS, not having the nutritional aspect of IBS. It basically is a single point solution targeting one thing. The beauty about TRLS is we are actually teaching people how to be effective self managers and focusing on the totality of the holistic aspect of IBS. We are the only ones that have this resilience based method. So for me, again, this speaks to, the fact that ACG or American College as well as GI on Demand has viewed us as the only effective academically validated solution that they wanna bring to the thirty three million plus patients with IBS and IBD should speak to the fact that they've all had opportunities to speak to every person in this space, and TRLS has been the one that has been the most effective change of human behavior. So I hope that sort of gives you a handle on the idea that the folks that are making decisions about what gets into the hands of GI providers across the country like myself have been vetted, and we have been found to be the most impactful and effective.
28:45 So, thank you for, congratulations on the Sherman Prize. And the question is why do I not think the market is acknowledging the progress in the business?
28:56 Well, I would need a lot of alcohol to have that discussion, but, really, I think a lot of it is just understanding what we're doing. And I'll be honest, I have specifically strategically been insular for the moment at getting the buy in of those folks who really are been my friends, my advisers, and sort of across the IBD centers across the country. Everyone knows it's a good idea. The question is, how are you gonna get it paid for? And that was most of the discussion over the year was really trying to figure out what's the best business model. I get consumers on? Can I get it paid for in the interim to really build data?
29:36 And now that we've opened up, now that the CCFA has recognized us as their partner for their members, now that we have the credibility of the GI sis of our National GI Society, I think and now that we have the messaging honed in to exactly what we do, I think the next six months is going to be a very, very big difference for TRELLUS. And sort of what I'm banking on is that the message is gonna be pretty clear. Also, it's Julian here. One thing I think is important for everyone to understand is we were getting a track record of not particularly delivering. And in the last ten weeks, we have delivered more than in the considerable amount of time before that. And the company now is on such a strong footing in terms of moving forward patient engagement, contract sign, all these things that didn't seem to be coming through have now come through because Mala has a reputation within The US that and she keeps telling me globally within The US that I'm humble about the whole thing. People respect her.
30:44 We have made so much progress since Mara has been CEO. And I think that's now we're looking at rebuilding the confidence in TRLS with shareholders, with fund managers sure that they understand that this business is really going places. So I would like to think from now on, from this call that MALA is making, from now on, we will see significant progress within well, we are seeing it already, but shareholders will see significant progress and a lot more news coming out to the market. Yeah. I think that was one of the questions, which is about, you know, how are we gonna manage PR going forward and how are we gonna PR coming forward. That's what I'm gonna have to do, clearly. It wasn't for lack of them asking us for more news. And part of it has been we've been honestly disciplined because I'm the type of person that if it's out there, I need to deliver on it. It's just the way that my DNA is. So for me, now that I was able to lock in a lot of our our new customer channels and the credibility and the support of the societies and also locking in and moving even now to employer based contracting, not just select groups of employees at Sinai as an example, and now across big employers in New York State being able to, drive contracting, I think that's sort of the traction. And, you know, I think you'll start to see a lot more news flow.
32:06 And a lot of it was not just, oh, we signed with, but a lot of it, what does that mean for the business and the and the revenue? And I think that's where you're gonna start to see some more news flow around making it clear about the financial benefits of that contract and not just making an announcement. I think that's sort of where I've been, and maybe that's, you know, where I've just been in my transparency is the way that I deliver, I need to deliver, and that's really what my focus has been. And there are a couple of most of this, a couple of questions regarding our current cash position. So about cash position at the moment and the projections for which took us out to early twenty twenty five are based on limited revenue. The revenue so the customer base has started to increase over the last well, since early July, since Marla took over and started driving the company in the correct in the right direction.
32:58 We see that revenue increasing quarter by quarter moving forward as more and more customers come onto the platform. It doesn't from the one of the slides you can see earlier on, you can see that it doesn't take a significant amount of customers out of the entire market itself to come onto the platform to start making the business revenue generating, which will extend to our current cash run rate, but also to become profitable. I think it's more point two or more point 4% of the entire more point 4% or not more point 4% of the entire marketplace to get us into a position. And that's just from monthly fees where we will become profitable. And that's excluding some of the other revenue opportunities which Marla has highlighted and discussed.
33:46 So we we do feel there's there will be sufficient cash within the business moving forward to get us to a position where we will be profitable. So where the question was, is this a realistic expectation? Yes. It is a realistic expectation. Of But, course, you have to deliver the patience, which is what we're doing. But it because we're not looking at 50% market share. It is a very much a realistic expectation that we can deliver on that. I think those are mainly the questions. So I don't know Well, I think the one Was there another does the rest of the management team bring to the to the table? Well, just to give a background on Steve, Steve worked with me way back in the VBI days. He's a very experienced PLC CFO.
34:34 He's done a tremendous job in working with Mala and Alan to reduce the spend, but it wasn't just your archetypal getting rid of staff. Steve and Alan worked with companies to reduce the spend on software development, reduce the spend on consultancy to get the to get the company down to nineteen, twenty people, most of which are experts in dealing with patients. And so Steve's acted incredibly quickly to deliver that. And as long as there's further, more improvements to be made as well. Okay. And alongside that, Aled has Nava can't do everything. So Aled has been very engaged with the team behind the scenes, making sure they're all pointing in the right direction, supporting Steve, getting out into The US, and making sure that they the the whole whole team are are pointing in the right direction and supporting Mala and delivering what we need to deliver.
35:32 And it comes with a wealth of experience from AstraZeneca. So we really have a new very hungry team that really want to succeed. In business. Yeah. My favorite question is this last question, which is how about the people that are experiencing a life changing moment at TRLS? And I think that's exactly. The question was, you know, how does referring to some of the testimonials here talk about my own experience and have have I had the opportunity to engage with any members directly? So, the answer to all of that is yes. And every week, we actually have a a resilience team, and we review the experiences of the patients where we can improve, what else are they asking for, what else do we need to develop.
36:19 And, you know, these are just three examples of the many of the lives we're changing. I mean, the idea is when you listen and say, for the first time in my life, I'm actually able to do a girls trip, or for the first time in my life, I'm actually able to take my pills or my injections and not have to have the anxiety or be able to not have to wear a diaper on the subway because they have confidence in being able to manage their symptoms, that I hear every week. So I am intimately connected every week with how patients are feeling and doing so that we continuously deliver the product to meet the needs of the end user. And that's really, I think, what has been my you know, the the sort of what makes me feel good every week to know that we are we need to push forward as hard as we can is because of the coming from the members directly in the lives that we're changing.
37:18 I did see one question on what do I think of what do we think of the current share price? Well, if you look at the development of the whole platform, the launch of the whole platform, the onboarding of patients, the drive into Mount Sinai, the contract signed, the Mount Sinai IGI on demand, and the fact that patients are coming on board and that we're trading at about 50% of the cash. I'll leave it up to you to think about what I think because you have a price. I think we all feel the same. Yeah. And, you know, there was a quest sorry. Did you have something to say? No. No. Okay. There is a question on how do I know that this resilience method is better than traditional and fair. Existing treatments are meds that don't work for most IBS patients.
38:07 It's really diet is the, diet is really the only way a lot of irritable bowel syndrome patients, for example. But in IBD, we know because in our original paper, we actually had patients who went on the platform and those who did not. So we had a control group. And I can tell you that the hospitalization rate, the steroid use, the opioid reduction we saw in those who were in the resilient self management program versus those who didn't, there was an increase in hospitalizations by sixty five percent in those who were being managed with any other solution out there. So it really sort of shows you that even within Mount Sinai, which is a fabulous delivery of of care for IBD patients, we still made tremendous progress by those who are enrolled in this resilience program versus those that did not. So I think you know, and I've been doing this for twenty five years. So I could tell you that whatever was out there before our resilience program, it wasn't impacting health outcomes. We were just managing patients with biologics, steroids, opioid utilization. We were not changing behavior.
39:18 And so the fact that we have finally have a solution that actually changes health behaviors, I think, sort of trumps a lot of other historical ways that we've tried, including myself, for a quarter of a century trying to actually move the needle on health outcomes. And one of the last questions is whether or not there are other ways that we may bring solutions, including whether diagnostic tests are gonna be brought. I think right now because, again, TRELLUS is not prescribing. We're not diagnosing. We're not treating. We're actually supporting and coordinating and delivering sort of these behavioral solutions. That a lot of it is gonna be more partnerships, less so sort of delivering directly any type of prescribing diagnostic test.
40:04 But there's so much opportunity for TRLS to get to the end user that we've already had. Many people have asked whether or not we can partner, maybe partner and say this is our preferred sort of partnership lab, whatever is gonna be on the table. But, again, I think the value of TRELLUS is really partnering with businesses that need the end user to be able to have better self management so they can actually stay on drug, lower the cost of care, stop using the emergency room, stop using opioids, stop going to surgery, stop going to the hospital, and that's where the real money is is really in the cost savings for all of our b to b customers. And I think that while it's missing out that we keep forgetting to say this, but the vast majority of IBD sufferers, as you can see from the slide, are 20 years of age when they first get this.
40:56 It's a lifelong chronic condition where people really need help with their resilience and mental health. And so it's a it's a chronic home for the young. So So it's Yeah. A lot of these diseases are diagnosed, you know, childhood or eighteen to twenty two. So we're talking about decades of disability that we're preventing. I mean, that's that is in itself, I can tell you from both an end user as well as a as a someone who's paying other than the end user that the cumulative cost of IBD over a lifetime is over $800,000,000,000 to the health plans. They're very much aware of this. And so a lot of it is being able to partner with folks like us who could actually contain the cost. That's great. Marla, I might I might just jump in there on the basis if you've answered every question that's coming from investors. So thank you to everybody for your engagement this afternoon. Afternoon. And if any further questions come in, Marla, we'll make those available after I today's know investor feedback will be particularly important to you and to the Board, and I'll shortly redirect investors on the call to give you their thoughts and expectations.
41:58 But before doing so, I wonder if I may, Marla, just ask you for a few closing comments to wrap up with. Yeah. I mean, I think the slide is enough to close the the talk on. You know, realistically, imagine, you know, the fact that in the last ten weeks, we've actually either signed or in late stage discussions of every contract we said we've been wanting to sign for over a year. We've also been able to get patients on the platform. We've reconfigured the entire platform to deliver across North America, and now we're gonna be able to reach to every type of provider or consumer that's out there that can benefit from our solution. I'm not sure there's much more that could have been done in the last ten weeks to drive this business forward. That's great. Marla, Julian, Steven, thank you very much indeed for updating investors this afternoon. Can I please ask investors not to close this session as we now automatically redirect you for the opportunity to provide your feedback in order the management team can better understand your views and expectations?
42:54 This will only take a few moments to complete, but I'm sure will be greatly valued by the company. On behalf of the management team of TRELLUS HEALTH PLC, we'd like to thank you for attending today's presentation. Good afternoon to you.
Follow Trellus Health PLC into a list and get an email when it puts out news.
CEO at TRELLUS HEALTH PLC
IR at TRELLUS HEALTH PLC
CFO at TRELLUS HEALTH PLC